Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Piperlotine A

$580

  • Brand : BIOFRON

  • Catalogue Number : AV-B03048

  • Specification : 95%

  • CAS number : 389572-70-7

  • Formula : C14H17NO2

  • Molecular Weight : 231.29

  • PUBCHEM ID : 773630

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B03048

Analysis Method

HPLC,NMR,MS

Specification

95%

Storage

-20℃

Molecular Weight

231.29

Appearance

Powder

Botanical Source

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

COC1=CC=C(C=C1)C=CC(=O)N2CCCC2

Synonyms

2-Propen-1-one, 3-(4-methoxyphenyl)-1-(1-pyrrolidinyl)-/3-(4-Methoxy-phenyl)-1-pyrrolidin-1-yl-propenone/3-(4-Methoxyphenyl)-1-(1-pyrrolidinyl)-2-propen-1-one

IUPAC Name

(E)-3-(4-methoxyphenyl)-1-pyrrolidin-1-ylprop-2-en-1-one

Applications

Density

1.1±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

217.5±22.9 °C

Boiling Point

436.0±24.0 °C at 760 mmHg

Melting Point

117-118℃

InChl

InChI=1S/C14H17NO2/c1-17-13-7-4-12(5-8-13)6-9-14(16)15-10-2-3-11-15/h4-9H,2-3,10-11H2,1H3/b9-6+

InChl Key

JYEDISZKFNNREA-RMKNXTFCSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:389572-70-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27589595

Abstract

Objective
To describe trends in the prevalence of diabetes among hospitalized HIV-infected patients between 1997 and 2012 in Spain and compare them with those of age- and sex-matched non-HIV-infected patients.

Methods
The study was based on Spanish national hospital discharge data. We performed a retrospective study for the period 1997-2012. HIV infection (HIV-infected versus non-HIV-infected [control group])and calendar period in relation to widespread use of combination antiretroviral therapy (cART) (1997-1999; 2000-2003; 2004-2007 and 2008-2012), were the exposure variables The outcome variables were diagnosis of diabetes and in-hospital mortality (IHM).

Results
From 1997 to 2012, we identified 91,752 cases of diabetes: 15,398 in the HIV-infected group (403,277 hospital admissions) and 76,354 in the non-HIV-infected group (1,503,467 hospital admissions). Overall, HIV-infected patients had lower prevalence values for diabetes than non-HIV-infected patients throughout the follow-up (3.8% vs. 5.1%; p<0.001). The prevalence of diabetes increased 1.56-fold among non-HIV-infected patients and 4.2-fold among HIV-infected patients. The prevalence of diabetes in females was almost twice as high in HIV-infected patients as in non-HIV-infected patients during the last study period (4.72% vs. 2.88%; p<0.001). Diabetes showed a protective effect against IHM throughout the study period (aOR = 0.70; 95%CI, 0.65-0.75). Conclusions During the cART era, the prevalence of diabetes has increased sharply among HIV-infected hospitalized patients compared with matched non-HIV-infected subjects. The prevalence of diabetes is rising very fast among HIV-infected women. Diabetes has a protective effect on IHM among HIV-infected patients. Nevertheless, our study has several limitations. No information is available in the database used on important sociodemographic characteristics and relevant clinical variables including duration of the HIV infection, treatments used, drug resistance, treatment adherence or CD4 count, among others. Also, it is possible that increase of diabetes prevalence could reflect the improvement in recording habits.

Title

Fifteen-Year Trends in the Prevalence of Diabetes among Hospitalized HIV-Infected Patients in Spain (1997-2012)

Author

Alejandro Alvaro-Meca,1 Rodrigo Jimenez-Garcia,#1,* Isabel Jimenez-Trujillo,1 Valentin Hernandez-Barrera,1 Javier de Miguel-Diez,2 Salvador Resino,#3 and Ana Lopez-de-Andres#1

Publish date

2016;